COMPANY OVERVIEW

syntrix pharmaceuticals

---

LOCATION

Auburn, WA, USA

---

THERAPEUTIC AREAS

Oncology

Pain

---

WEBSITE

https://syntrixbio.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Oct 27, 2020

Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial Campaign Now Encompassing 5 Solid Cancer Types Plus Myelodysplastic Syndromes

Feb 4, 2020

Syntrix Discovers Desmetramadol is G-Protein Biased Opioid Receptor Agonist

Oct 31, 2019

Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT

Jun 20, 2019

Syntrix Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA (pembrolizumab) in Metastatic Melanoma

Jun 4, 2019

Syntrix Pharmaceuticals Announces Publication of Positive Double-Blind Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities

For More Press Releases

---